Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Plasma cell 1Other solid neoplasm 1Lymphoid 1Gynecologic 1CNS 1

Conditions

Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1

Interventions

Cyclophosphamide 345Rituximab 309Vincristine 160Doxorubicin 157venetoclax 156fludarabine 153Specimen Handling 152Prednisone 152Biopsy 122obinutuzumab 117Magnetic Resonance Spectroscopy 117Lenalidomide 110Dexamethasone 106Cytarabine 100ibrutinib 96Etoposide 94fludarabine phosphate 87Methotrexate 86acalabrutinib 79zanubrutinib 73Bendamustine Hydrochloride 73pembrolizumab 63blinatumomab 63CT-P10 61Gemcitabine 52glofitamab 45Nivolumab 45Calcium Dobesilate 45Mercaptopurine 44prednylidene 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Antibodies, Monoclonal × Lymphoid × 1 year × Clear all
NCT06550141 2025-11-14

Emapalumab Prevention of CAR-T Cell Associated Toxicities

Massachusetts General Hospital

Phase 2 Recruiting
28 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡